Lenabasum

Summary

Lenabasum (CHEMBL456341) is a phase-3 clinical-stage small molecule targeting CNR1 and CNR2; indicated across 4 conditions including dermatomyositis and diffuse scleroderma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 2 (CNR1, CNR2)
• Indications: 4 conditions
• Clinical trials: 7
• Chemistry: 400.5 Da · C25H36O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL456341
Name	Lenabasum
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	3083542
Molecular formula	C25H36O4
Molecular weight	400.5
InChIKey	YCHYFHOSGQABSW-RTBURBONSA-N

SMILES: CCCCCCC(C)(C)C1=CC(=C2[C@@H]3CC(=CC[C@H]3C(OC2=C1)(C)C)C(=O)O)O

IUPAC name: (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid

Also known as: Ajulemic acid, CPL-7075, CPL7075, CT-3, HU-239, IP-751, JBT-101, Lenabasum, Resunab, LENABASUM, AJULEMIC ACID

Patent coverage: 776 distinct patent families (1,313 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,168 (89%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CNR1	CB1 receptor	Agonist	7.49	0%	P21554
CNR2	CB2 receptor	Agonist	6.77		P34972

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Cannabinoid receptor 1, Cannabinoid receptor 2.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CNR1	8.24	Ki	5.7	nM	CHEMBL_ACT_14655724
CNR1	7.49	Ki	32.3	nM	CHEMBL_ACT_14574041
CNR2	6.77	Ki	170.5	nM	CHEMBL_ACT_14574075
CNR1	6.03	EC50	927	nM	CHEMBL_ACT_14574112

Target pathways

Aggregated over 2 target gene(s): CNR1, CNR2.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Class A/1 (Rhodopsin-like receptors)	2	CNR1, CNR2
G alpha (i) signalling events	2	CNR1, CNR2

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	2
adenylate cyclase-activating G protein-coupled receptor signaling pathway	2
cannabinoid signaling pathway	2
signal transduction	2
G protein-coupled receptor signaling pathway	2
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
axonal fasciculation	1
glucose homeostasis	1
retrograde trans-synaptic signaling by endocannabinoid	1
regulation of presynaptic cytosolic calcium ion concentration	1
response to amphetamine	1
inflammatory response	1
immune response	1
leukocyte chemotaxis	1
negative regulation of synaptic transmission, GABAergic	1

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
dermatomyositis	3	MONDO:0016367	EFO:0000398
diffuse scleroderma	3	MONDO:0005019	EFO:0000404
cystic fibrosis	2	MONDO:0009061	MONDO:0009061
systemic lupus erythematosus	2	MONDO:0007915	MONDO:0007915

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03398837	PHASE3	TERMINATED	Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
NCT03813160	PHASE3	COMPLETED	Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
NCT02465437	PHASE2	TERMINATED	Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
NCT02465450	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis
NCT02466243	PHASE2	TERMINATED	Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
NCT03093402	PHASE2	COMPLETED	JBT-101 in Systemic Lupus Erythematosus (SLE)
NCT03451045	PHASE2	COMPLETED	Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

128 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
CANNABIDIOL	ChEMBL	Phase 4 (approved)	CNR1, CNR2
DRONABINOL	ChEMBL	Phase 4 (approved)	CNR1, CNR2
NABILONE	ChEMBL	Phase 4 (approved)	CNR1, CNR2
RIMONABANT	ChEMBL	Phase 4 (approved)	CNR1, CNR2
CANNABINOL	ChEMBL	Phase 3	CNR1, CNR2
DEXANABINOL	ChEMBL	Phase 3	CNR1, CNR2
EPIGALOCATECHIN GALLATE	ChEMBL	Phase 3	CNR1, CNR2
OTENABANT	ChEMBL	Phase 3	CNR1, CNR2
TARANABANT	ChEMBL	Phase 3	CNR1, CNR2
CANNABIDIVARIN	ChEMBL	Phase 2	CNR1, CNR2
CANNABIGEROL	ChEMBL	Phase 2	CNR1, CNR2
DELTA-8-TETRAHYDROCANNABINOL	ChEMBL	Phase 2	CNR1, CNR2
IBIPINABANT	ChEMBL	Phase 2	CNR1, CNR2
PRS-211375	ChEMBL	Phase 2	CNR1, CNR2
REDAFAMDASTAT	ChEMBL	Phase 2	CNR1, CNR2
S-777469	ChEMBL	Phase 2	CNR1, CNR2
SURINABANT	ChEMBL	Phase 2	CNR1, CNR2
TEDALINAB	ChEMBL	Phase 2	CNR1, CNR2
TETRAHYDROCANNABIVARIN	ChEMBL	Phase 2	CNR1, CNR2
TAFAMIDIS	ChEMBL + PubChem	Phase 4 (approved)	CNR1
ACARBOSE	ChEMBL	Phase 4 (approved)	CNR1
ALCLOMETASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	CNR1
ALPRAZOLAM	ChEMBL	Phase 4 (approved)	CNR1
AMCINONIDE	ChEMBL	Phase 4 (approved)	CNR1
AMPRENAVIR	ChEMBL	Phase 4 (approved)	CNR1
ATENOLOL	ChEMBL	Phase 4 (approved)	CNR1
BECLOMETHASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	CNR1
BEPRIDIL	ChEMBL	Phase 4 (approved)	CNR1
BIFONAZOLE	ChEMBL	Phase 4 (approved)	CNR1
BUCLIZINE	ChEMBL	Phase 4 (approved)	CNR1
BUSPIRONE	ChEMBL	Phase 4 (approved)	CNR1
CAFFEINE	ChEMBL	Phase 4 (approved)	CNR1
CALCITRIOL	ChEMBL	Phase 4 (approved)	CNR1
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	CNR1
CARBENOXOLONE	ChEMBL	Phase 4 (approved)	CNR1
CEFDINIR	ChEMBL	Phase 4 (approved)	CNR1
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	CNR1
CICLESONIDE	ChEMBL	Phase 4 (approved)	CNR1
DEXAMETHASONE	ChEMBL	Phase 4 (approved)	CNR1
ECONAZOLE	ChEMBL	Phase 4 (approved)	CNR1
EFAVIRENZ	ChEMBL	Phase 4 (approved)	CNR1
ENZALUTAMIDE	ChEMBL	Phase 4 (approved)	CNR1
ERYTHROMYCIN	ChEMBL	Phase 4 (approved)	CNR1
ETHAMBUTOL	ChEMBL	Phase 4 (approved)	CNR1
FELODIPINE	ChEMBL	Phase 4 (approved)	CNR1
FENOFIBRATE	ChEMBL	Phase 4 (approved)	CNR1
FENTICONAZOLE	ChEMBL	Phase 4 (approved)	CNR1
FEXOFENADINE	ChEMBL	Phase 4 (approved)	CNR1
FLUOXETINE	ChEMBL	Phase 4 (approved)	CNR1
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	CNR1
FLUTICASONE FUROATE	ChEMBL	Phase 4 (approved)	CNR1
GLIPIZIDE	ChEMBL	Phase 4 (approved)	CNR1
IMIPRAMINE	ChEMBL	Phase 4 (approved)	CNR1
INDOCYANINE GREEN ACID FORM	ChEMBL	Phase 4 (approved)	CNR1
KETOTIFEN	ChEMBL	Phase 4 (approved)	CNR1
LOFEPRAMINE	ChEMBL	Phase 4 (approved)	CNR1
LORCASERIN	ChEMBL	Phase 4 (approved)	CNR1
LOSARTAN	ChEMBL	Phase 4 (approved)	CNR1
MASOPROCOL	ChEMBL	Phase 4 (approved)	CNR1
MECLIZINE	ChEMBL	Phase 4 (approved)	CNR1